CTLA4 and neoplasm: However, the addition of anti-PD1, anti-CTLA-4, or both ICB therapies induced complete and sustained tumor regressions in mice treated with the B16-APOBEC3BACTIVE vaccine, but not in mice treated with the B16-APOBEC3BINACTIVE vaccine (Fig. 2c, d) (p = 0.0008 Log-Rank test with Holm–Bonferroni correction for multiple comparisons).